Celularity Inc
CELU1.300USD
+0.130+11.11%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
36.68M시가총액
손실P/E TTM
자세한 내용은 Celularity Inc 회사
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Celularity Inc 정보
종목 코드 CELU
회사 이름Celularity Inc
상장일May 23, 2019
CEOHariri (Robert J)
직원 수123
유형Ordinary Share
회계 연도 종료May 23
주소170 Park Ave
도시FLORHAM PARK
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호07932
전화19087682170
웹사이트https://celularity.com/
종목 코드 CELU
상장일May 23, 2019
CEOHariri (Robert J)
Celularity Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+3281.00%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+28847.00%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+3281.00%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+28847.00%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sat, Jan 3
마지막 업데이트: Sat, Jan 3
주주
주주 유형
주주
주주
비율
Genting Bhd
21.97%
Hariri (Robert J)
9.91%
Starr International Company, Inc.
5.30%
Lincoln Alternative Strategies LLC
4.27%
C.V. Starr & Co., Inc.
2.65%
기타
55.90%
주주
주주
비율
Genting Bhd
21.97%
Hariri (Robert J)
9.91%
Starr International Company, Inc.
5.30%
Lincoln Alternative Strategies LLC
4.27%
C.V. Starr & Co., Inc.
2.65%
기타
55.90%
주주 유형
주주
비율
Corporation
26.24%
Individual Investor
15.43%
Investment Advisor
8.72%
Insurance Company
2.65%
Investment Advisor/Hedge Fund
1.30%
Hedge Fund
0.38%
Research Firm
0.17%
Family Office
0.04%
기타
45.07%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
71
3.82M
13.73%
--
2025Q3
80
3.82M
16.36%
+119.97K
2025Q2
92
3.70M
17.46%
+189.07K
2025Q1
120
3.51M
18.18%
-579.52K
2024Q4
135
3.39M
17.70%
+120.20K
2024Q3
149
3.27M
18.60%
+20.75K
2024Q2
160
3.32M
18.56%
+109.90K
2024Q1
166
3.20M
18.29%
-780.71K
2023Q4
164
3.20M
20.76%
-511.70K
2023Q3
164
3.71M
20.21%
+96.25K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Genting Bhd
6.34M
22.25%
--
--
Oct 30, 2025
Hariri (Robert J)
2.86M
10.04%
+3.28K
+0.11%
Oct 30, 2025
Starr International Company, Inc.
1.53M
5.37%
--
--
Oct 30, 2025
Lincoln Alternative Strategies LLC
1.23M
4.32%
+1.23M
--
Jul 14, 2025
C.V. Starr & Co., Inc.
764.07K
2.68%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
676.65K
2.38%
+176.52K
+35.29%
Sep 30, 2025
Ling (Geoffrey M. D.)
472.29K
1.66%
+192.42K
+68.75%
Dec 29, 2025
Diamandis (Peter)
441.18K
1.55%
+192.42K
+77.35%
Dec 29, 2025
Parks (Diane L.)
344.98K
1.21%
+192.42K
+126.12%
Dec 29, 2025
Levien (Vincent)
128.70K
0.45%
+125.00K
+3379.29%
Dec 29, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
비율0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
날짜
배당락일
유형
비율
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
